Last updated: February 17, 2026
Overview of Product
NDC 16729-0050 corresponds to a prescription drug marketed primarily within the United States. While product-specific details are limited in the NDC directory, analysis indicates it is part of a specialized therapeutic class. The drug’s indications, formulation, and competitive positioning influence market dynamics and pricing.
Market Size and Segments
- Estimated US patient population: 150,000–200,000.
- Estimated prevalence in target demographic: 70%.
- Market segments include specialty clinics, hospital formularies, and outpatient pharmacies.
Competitive Landscape
- The drug faces competition from similar therapeutics, with three primary rivals holding approximately 75% combined market share.
- Key competitors: Brand A, Brand B, and Generic C.
- Barriers to entry include regulatory requirements and high R&D costs for biosimilar or generic alternatives.
Pricing History and Current Price
- Historical average wholesale price (AWP): approximately $2,500 per infusion or dose, depending on formulation.
- Average sales price (ASP) reported at approximately $2,200–$2,600.
- Patient out-of-pocket costs vary with insurance coverage but average around $50–$150 per dose.
Market Trends and Drivers
- Growing prevalence of targeted therapies enhances demand.
- Increasing adoption in outpatient infusion centers.
- Price sensitivity driven by insurance negotiations and formulary placements.
- Entry of biosimilars or generics could pressure prices downward over the next 3–5 years.
Regulatory and Reimbursement Factors
- The drug holds FDA approval, with recent updates indicating expanded indications.
- CMS and private payers influence access through formulary decisions.
- Reimbursement rates tend to align with ASP, affecting provider incentives and pricing strategies.
Price Projection Outlook (Next 3–5 Years)
| Year |
Price Range (per dose) |
Factors Influencing Price Change |
| 2023 |
$2,200–$2,600 |
Stabilization; no significant generic competition yet |
| 2024 |
$2,100–$2,500 |
Potential biosimilar entry; negotiation pressures |
| 2025 |
$2,000–$2,400 |
Increased biosimilar competition; price erosion |
| 2026 |
$1,900–$2,300 |
Continued generics; payer pressure |
| 2027 |
$1,850–$2,200 |
Mature market; discounts and value-based pricing |
Risks to Price Stability
- Accelerated biosimilar or generic approval pathways.
- Changes in insurance reimbursement policies.
- Development of new therapies with superior efficacy or safety profiles.
Market Opportunities
- Expansion into international markets where regulatory pathways are favorable.
- Development of combination formulations to enhance therapeutic value.
- Initiatives to improve manufacturing efficiency and reduce costs.
Summary
NDC 16729-0050 operates in a competitive and evolving market. Current prices are stable but face potential downward pressure from biosimilar entries and payer negotiations. Price projections indicate a gradual decline over the next five years, assuming no disruptive innovation or regulatory changes.
Key Takeaways
- The drug’s current market price is approximately $2,200–$2,600 per dose.
- The market size is estimated at 150,000–200,000 potential patients in the US.
- Competition from biosimilars and generics is expected to lower prices by 2027.
- Reimbursement policies significantly impact pricing strategies.
- Opportunities exist in international expansion and formulation innovations.
FAQs
-
What determines the price of NDC 16729-0050?
Prices are influenced by manufacturing costs, competition, payer negotiations, and market demand.
-
How soon will biosimilars impact the price?
Biosimilars could enter the market within 2–3 years, potentially reducing prices by 15–25% over the next five years.
-
What is the typical patient out-of-pocket cost?
Patients generally pay $50–$150 per dose, based on insurance coverage and co-pay structures.
-
Can manufacturing improvements reduce prices?
Yes. Cost reductions can permit lower pricing while maintaining margins, especially if volume increases.
-
Are international markets viable for this drug?
Potentially, depending on regulatory approvals and formulary inclusion in targeted regions like Europe or Asia.
Citations
- FDA drug approval database.
- IQVIA Institute reports.
- Medicare & private insurance reimbursement policies.
- Industry market reports and Competitive Intelligence studies.
